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disease in the patients with hypertension among
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Objectives: Peripheral arterial disease (PAD) is associated with morbidity and mortality of coronary heart disease and
stroke. Hypertension is an independent risk factor for peripheral arterial disease. However, the prevalence and risk factors
of PAD in hypertensive patients have not been studied in China.
Methods: In order to investigate the prevalence of PAD and its risk factors in China, a cross-sectional study was carried out.
A total of 4716 patients with hypertension and 833 age-gender matched people without hypertension were recruited; age
40 to 75 years, from seven rural communities. PAD was defined as an ankle-brachial index (ABI) < 0.9 in either leg;
hypertension was defined as systolic blood pressure >140 mm Hg, diastolic blood pressure >90 mm Hg, or history of
antihypertensive drug use.
Results:The prevalence of PAD is 8.7% (n 408) in patients with hypertension (n 4716), higher than in people without
hypertension (5.0%, n  833, P  .004). Hypertensive patients with PAD were older, (61  8.6 vs 58  8.6, P < .01),
had more conventional cardiovascular risk factors including systolic blood pressure (170 22.6 vs 167 22.7, P< .01),
pulse pressure (72 19.7 vs 68 18.9, P< .01), blood glucose (5.8 2.2 vs 5.6 1.7, P< .05), total cholesterol (5.7
1.3 vs 5.5  1.1, P < .05), and serum uric acid (355  98.0 vs 293  86.2, P < .05) than the hypertensive patients
without PAD. After adjusting for gender, age, and other cardiovascular risk factors by using multiple logistical regression
analysis, PAD was still associated with current smoking (odds ratio [OR]  1.65, 95% confidence interval [CI]
1.18-2.29), history of stroke (OR 1.50, 95% CI 1.12-2.00), serum uric acid (OR 1.21, 95% CI 1.10-1.59), and total
cholesterol (OR  1.12, 95% CI 1.10-1.59).
Conclusion: This study reports, for the first time, the prevalence of PAD in Chinese patients with hypertension, which is
quite different from that in westerners, and that PAD is independently associated with conventional cardiovascular risk
factors. ( J Vasc Surg 2007;46:296-302.)Peripheral arterial disease (PAD) commonly results
from progressive narrowing of arteries in the lower extrem-
ities and is a manifestation of systemic atherosclerosis. It is
well known that PAD is associated with increased risk of
mortality from cardiovascular disease (CVD) and all causes
such as cerebral vascular diseases, renal disease, and diabetic
mellitus. Additionally, it is an independent risk factor for
mortality and morbidity in patients with CVD.1-4 PAD
carries a cardiovascular risk similar to that of coronary artery
disease (CAD); the American Heart Association (AHA)
and the National Cholesterol Education Program (NCEP)
recommend the same degree of risk-factor reduction in
patients with PAD as in those with CAD. Unfortunately,
most physicians under-treat risk factors in patients with
PAD when no other obvious cardiovascular symptoms are
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296present.5-7 Also, the prevention and treatment for PAD and
its risk factors did not attract the attention of a majority of
physicians in China.8
Despite using similar diagnostic criteria, prevalence of
PAD is quite different in ethnic groups.9,10 These observa-
tional data were predominantly based on studies from the
United States and Europe, and few data are available from
Asian countries, where the prevalence of PAD in the gen-
eral population has been reported to be low.11 In the
high-risk group with hypertension, the Systolic Hyperten-
sion in the Elderly Program (SHEP) Study shows that PAD
is an important predictor of mortality andmorbidity among
older adults with systolic hypertension.12 However, no
epidemiological study of PAD has been performed in the
hypertensives in Asian. Therefore, in order to improve the
diagnosis, prevention, and treatment of PAD in patients
with hypertension, a particular high risk group, we con-
ducted a cross-sectional study to survey the prevalence of
PAD and its risk factors.
METHODS
Study population. This community-based cross-
sectional study was conducted in the XinYang County, in
the middle region in China from 2004 to 2005. We used a
multistage cluster sampling method to select a representa-
tive sample of rural community residents aged 40 to 75
years. First, seven residential communities were randomly
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XinYang County. Secondly, 63 districts were randomly
selected from a total of 180 districts in the seven residential
communities. Subjects were excluded from the study when
they had any known diseases including heart failure, renal
failure, valvular heart disease or secondary hypertension,
and severe debilitating chronic illness (cancer, renal, or
hepatic diseases). A total of 13,444 subjects (5270men and
8174 women) completed the survey, yielding a response
rate of 84.9%. Among them, 5421 hypertensive patients
were identified and thoroughly examined. Hypertension
was defined as diastolic blood pressure (DBP) of 90 mm
Hg, systolic blood pressure (SBP) of 140 mm Hg,
physician diagnosis, or current medication for hyperten-
sion (as defined by WHO 1999). Valid information on
ankle-brachial blood pressure index (ABI) was available for
4812 subjects (89% of eligible persons). We excluded 96
participates with ABI 1.40, because these values have
been recognized to be consistent with noncompressible,
calcified arteries, and including these values might have
resulted in misclassification.9 Ultimately, 4716 subjects
(1606 men and 3110 women) were involved in the present
study. Meantime, 833 age-gender matched people without
hypertension (288 men and 545 women) were recruited as
normal blood pressure controls.
Ethical consideration. The study protocol was re-
viewed and approved by the ethical committees of the
FuWai and local hospitals. All participants gave their in-
formed consent before they were recruited and reported
themselves to be of Han nationality.
Collection of data. We identified eligible people by
their age and documents of residence and invited them to a
community clinic by letter or telephone. Each participant
was interviewed and completed a standardized question-
naire that included a range of demographic factors, medical
history, history of medications, and lifestyle. A current
smoker was defined as an individual currently smoking an
average of one or more cigarettes each day. An ex-smoker
was defined as an individual who previously smoked but no
longer smoked for 3 months or more. Participants who
reported that they were neither current smoker nor ex-
smoker were classified as having never smoked. Current
drinker was defined as average alcohol consumption of
more than 10 gram of pure alcohol per day for more than 1
year in the past 5 years.
ABI measurement and definition of PAD. ABI was
determined by using a standard protocol. Systolic blood
pressure (SBP) was measured using a portable Doppler
device (ES-101EX, HADECO, 8 MHz probe, Kawasaki,
Japan). After 5 minutes of rest, standard 12-cm cuff was
used tomeasure the systolic blood pressure in the each arm.
The cuff was then applied to each ankle. After the brachial
and posterior tibial arteries were palpated and ultrasound
gel applied, a Doppler stethoscope was used to measure
systolic blood pressure. The cuff was inflated to 20 mmHg
above the palpated SBP and deflated at 2 mmHg per pulse.
The first appearance of Korotkoffs sound was recorded as
SBP. The ABI for each leg was calculated as the SBP in theposterior tibial artery divided by the higher value of the two
arm SBPs; the higher arm SBP was used because of the
variation in arm blood pressures and the strong association
between PAD and subclavian stenosis.13 The lower value of
ABIs was used as the index value. An ABI0.9 and1.4 in
both legs was considered normal, and patients were diag-
nosed as having PAD if the value recorded for one of the
legs was 0.9.
Physical examination. Anthropometric measure-
ments of subjects who wore light clothing and were in bare
feet were conducted by experienced research staff. Height
was measured once to the nearest 0.1 cm, and weight was
measured in the upright position to the nearest 0.1 kg.
Body mass index (BMI) was calculated as weight in kilo-
grams divided by the square of height in meters. We mea-
sured waist circumference on standing subjects with a soft
tape midway between the lowest rib and the iliac crest. Hip
circumference was measured over the widest part of the
gluteal region.
Blood pressure (BP) was measured by trained profes-
sionals with a standardized mercury sphygmomanometer,
and one of three cuff sizes (regular adult, large, or small)
was chosen on the basis of the circumference of the partic-
ipant’s right arm. All participants were advised to avoid
alcohol, cigarette smoking, coffee/tea, and exercise for at
least 30minutes before their BPmeasurement. The average
of three readings with the participant in the sitting position
after at least 5 minutes of rest, recorded at least 30 seconds
apart, was obtained for analysis.
Overnight fasting blood specimens were obtained from
an antecubital vein. Serum was separated on-site, then
transported on dry ice to Beijing center laboratory, and
stored at 70°C until measurement. Concentrations of
total cholesterol (TC), high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol,
triglycerides (TG), fasting glucose, and uric acid were as-
sayed by an automatic analyzer (Hitachi 7060, Hitachi,
Tokyo, Japan).
Diagnosis of cardiovascular disease. The question-
naire that was administered was designed to determine the
history of cardiovascular disease, type 2 diabetes mellitus,
hypertension, and medication. There were 429 (9.1%)
cases of coronary artery disease, diagnosed by coronary
arteriography, a previous myocardial infarction, or surgery
or coronary revascularization. There were 509 (10.8%)
cases of stroke. Strokes were defined as events requiring
hospitalization or symptom of neurologic deficit; this infor-
mation was verified from local hospital records, and 81% of
the cases were confirmed using computed tomography and
magnetic resonance imaging. Subjects with a fasting plasma
glucose level 7.0 mmol/l and/or who were receiving
antidiabetic medications were diagnosed with diabetes mel-
litus. Three hundred eighty-seven patients (8.2%) were
diagnosed as diabetes mellitus.
Statistical analysis. All subjects were divided into two
groups according ABI values. Differences in continuous
variables between two groups were compared with a t test
and differences in categorical variables were measured with
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ratios (ORs) and their 95% confidence intervals (CIs).
Potential confounders (age, gender, BMI, TG, UA, SBP,
smoking, alcohol consumption, histories of CAD, stroke,
or DM) were adjusted. A 2-tailed probability value of.05
was considered significant. Analyses were performed with
SPSS 11.0 (SPSS Inc, Chicago, Ill) forWindows (Microsoft
Corp, Redmond, Wash).
The authors had full access to the data and take full
responsibility for its integrity. All authors have read and
agree to the manuscript as written.
RESULTS
Baseline characteristics. General characteristics of the
4716 hypertensive patients (1606 men, 3110 women) and
833 people without hypertension (288 men, 545 women)
are given in Table I. In the group of hypertensive patients,
percentage of patients with history of stroke (10.8%), cor-
onary artery disease (9.1%), diabetes mellitus (8.2%), and
current smoking (16.7) was relatively lower in our study
than in subjects in previous studies;14,15 the average age of
patients with hypertension was 58.2 years, and it was 54.4
years in people without hypertension.
Prevalence of PAD. The prevalence of PAD is 8.7%
(n 4716) in middle-aged patients with hypertension and
significantly higher than the people without hypertension
(5.0%, n  833, P  .004). The prevalence of PAD
increased with age in both genders. No clear gender differ-
Table I. Demographic, anthropometric, and plasma
biochemical characteristics of subjects with hypertension
(n  4716) and subjects without hypertension (n  833)
Characteristics Hypertensives Normotensives
Number of subjects 4716 833
% male 34.1 34.6
Mean age (years) 58.2  8.6 54.4  8.9
Systolic blood pressure (mm Hg) 166.8  22.7 120.0  11.5
Diastolic blood pressure
(mm Hg)
98.3  11.7 78.7  6.9
Pulse pressure (mm Hg) 68.5  19.0 41.3  9.9
Body mass index (kg/m2) 26.0  3.4 24.1  3.3
Waist hip index 0.9  0.1 0.9  0.1
Fasting glucose (mmol/L) 5.6  1.8 4.9  1.6
HDL cholesterol (mmol/L) 1.6  0.3 1.5  0.3
LDL cholesterol (mmol/L) 3.2  0.9 2.7  0.8
Total cholesterol (mmol/L) 5.6  1.1 5.1  1.1
Triglycerides (mmol/L) 1.8  1.3 1.4  1.0
Uric acid (mmol/L) 302.8  88.3 268.5  75.9
Diabetes mellitus (%) 8.2 5.4
History of CAD (%) 9.1 3.0
History of stroke (%) 10.8 2.6
Current smokers (%) 16.7 10.7
Current drinkers (%) 19.4 12.4
ABI 0.9 (%) 8.7 5.0
0.9 ABI 1.30 (%) 91.3 95.0
HDL, High-density lipoprotein; LDL, low-density lipoprotein; CAD, cor-
onary artery disease.
Values are mean  SD, or percentages.ences were observed in PAD prevalence (Fig). Table IIshows the prevalence of PAD by selected population char-
acteristics. The prevalence of PAD was 7.5% among hyper-
tensives age at 40 to 50 years, 8.9% among those at 50 to 60
years, and 10.7% among those at 60 to 75 years. The
prevalence of PAD was 12.5% among individuals with
stroke history, 8.4% in the individuals without stroke,
10.1% among individuals of coronary artery disease, and
8.7% in the individuals without coronary artery disease.
Among individuals with diabetes, 10.3% had PAD and 8.7%
in individuals without diabetes. Prevalence of PAD was
associated with smoking status, with a prevalence of 11.5%
among current smokers, and 8.3% among ex-smokers. The
prevalence of PAD among current drinkers was 11.4%.
Cardiovascular Disease Risk Factors and PAD.
Fig. Prevalence of peripheral arterial disease (PAD) by age and
gender, patients with hypertension aged 40 to 75 years in China
(n  4716).
Table II. Prevalence of peripheral arterial disease in
Chinese hypertensive patients aged 40 to 75 years
(n  4716)
PAD (ABI 0.9) P value
Total 8.7%
Gender
male 9.3% .4
female 8.6%
Age groups (years)
40-50 7.5% .001
50-60 8.9%
60-75 10.7%
History of stroke
Yes 12.5% .002
No 8.4%
Diabetic mellitus
Yes 10.3% .28
No 8.7%
History of CAD
Yes 10.1% .33
No 8.7%
Drinking status
current drinker 11.4% .003
ex-drinker 8.2%
Smoking status
current smoker 11.5% .004
ex-smoker 8.3%
CAD, Coronary artery disease; PAD, peripheral arterial disease; ABI, ankle-
brachial index.Table III shows the distribution of cardiovascular disease
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PAD. The patients with PAD were older (P  .002), had
higher SBP (P  .003), pulse pressure (P  .001), blood
glucose (P .028), total cholesterol (P .02), serum uric
acid (P  .028), and slightly lower BMI (P  .01). They
also had higher ratio of current smoker (P .004), current
drinker (P  .003), and history of stroke (P  .002). The
distribution of gender, WHI, diabetes mellitus, and history
of CAD were similar in both groups.
Risk factors for PAD. In our study, patients with
hypertension had higher risk of PAD than patients without
hypertension (OR  1.58, 95% CI 1.16-2.16, P  .004).
Among hypertensive patients, the adjusted and unadjusted
ORs of PAD are shown in Table IV. In age- and gender-
adjusted analysis, current smoking (OR  1.63, 95% CI
1.17-2.26), stroke (OR  1.50, 95% CI 1.13-2.22) were
associated with PAD. Serum uric acid, total cholesterol,
and age were also associated with PAD, with ORs of 1.25
(95% CI 1.10-1.42), 1.12 (95% CI 1.03-1.22), and 1.02
(95% CI, 1.01-1.03), respectively. BMI was negatively
associated with PAD (OR  0.97, 95% CI 0.94-0.99).
However, no association was found in diabetes mellitus or
CADwith PAD. After adjustment of potential confounders
by usingmultiple logistical regression analysis, independent
risk factors are current smoking (OR 1.65, 95% CI 1.18-
2.29), stroke (OR  1.50, 95% CI 1.12-2.00), total cho-
lesterol (OR  1.12, 95% CI 1.02-1.23), and serum uric
acid (OR  1.21, 95% CI 1.10-1.59). BMI remained
negatively associated with PAD (OR  0.96, 95% CI
Table III. Cardiovascular disease risk factors among hype
Chinese patients aged 40 to 75 years (n  4716)
Hypertensives wit
0.9 ABI 1.40 (n 
Ankle-brachial index 1.07  0
Male (%) 35.5
Age (years) 58.1  8
Systolic blood pressure (mm Hg) 166.6  2
Diastolic blood pressure (mm Hg) 98.2  1
Pulse perssure (mm Hg) 68.4  1
Body mass index (kg/m2) 26.0  3
Waist hip index 0.9  0
Fasting glucose (mmol/L) 5.6  1
HDL-cholesterol (mmol/L) 1.6  0
LDL-cholesterol (mmol/L) 3.2  0
Total cholesterol (mmol/L) 5.5  1
Triglyceride (mmol/L) 1.7  1
Uric acid (mmol/L) 293.4  8
Diabetic mellitus % 8.0
History of CAD % 9.1
History of stroke % 10.5
Current smoking % 16.3
Current drinking % 18.7
HDL,High-density lipoprotein; LDL, low-density lipoprotein; CAD, coron
no significant difference, P  .05.
Values are mean  SD, or percentages.
P: t-test or 2 test ABI 0.9 to 1.40 vs ABI  0.9.0.93-0.98).DISCUSSION
To the best of our knowledge, this report is the first to
observe the prevalence and risk factors of PAD among
Chinese hypertensives that have a high risk for developing
cardiovascular diseases. The present study showed that the
prevalence of PAD was 8.7% among patients with hyper-
tension aged 40 to 75 years. According to the prevalence of
hypertension in China16 and the PAD in this study, about
10 million hypertensives have PAD in the age of 40 to 75
years group.
Our data confirmed that the prevalence of PAD in
patients with hypertension is higher than people without
hypertension. In other Asian general populations, the prev-
alence of PAD is 5.0% in elderly Japanese (60 to 70 years);
2.2% in Korean men, and 1.8% in Korean women (45 to 74
years).17,18 The prevalence in our study (8.7%) was lower
than another study in Beijing urban (15.3% in elder sub-
jects, 60 to 95 years).15 The difference between the two
studies may result from the differences in age (54.4 vs 68.5
years), social-economic status, lifestyle, and more cardio-
vascular disease in Beijing urban study, than in our study
(50% vs 10%).
In addition, prevalence (8.7%) in this population is
lower than reported previously in the SHEP study
(19.7%).19 In addition to the differences in age, ethnicity
may contribute to the variety. The Hawaii study shows
lower age-specific PAD prevalence in Japanese Americans
than in non-Hispanic whites (NHWs).9 A new study proves
ives with and without peripheral arterial disease in
PAD
8), %(SD)
Hypertensives with PAD
ABI 0.9 (n  408), %(SD) P value
0.82  0.1 .000
33.5 NS
60.5  8.6 .002
170.1  22.6 .003
98.6  11.3 NS
71.5  19.7 .001
25.6  3.5 .010
0.9  0.1 NS
5.8  2.2 .028
1.6  0.3 NS
3.3  1.0 NS
5.7  1.3 .021
1.8  1.5 NS
354.5  98.4 .002
9.6 NS
10.5 NS
15.4 .002
21.6 .004
24.8 .003
ery disease; PAD, peripheral arterial disease; ABI, ankle-brachial index;NS,rtens
hout
430
.1
.6
2.7
1.7
8.9
.4
.1
.7
.3
.9
.1
.3
6.2
ary artthat Asians have a lower PAD prevalence than do NHWs
eride,
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by levels of diabetes, hypertension, and body mass index.10
Risk factor for PAD may also vary in different ethnic
groups. We demonstrate that current smoking, history of
stroke, high uric acid levels, and high total cholesterol levels
are the risk factors for PAD.
Among traditional risk factors, current smoking was
strongly associated with the risk of PAD in our study. These
data are in line with the majority of 12,20,21 but not all
studies.22,23 Smoking cessation is considered as a first-line
treatment among smokers with PAD.24 Our data support
the conclusion of the Cardiovascular Heart Study,2 in
which smoking is the strongest predictor of reduction of
ABI. In the Framingham Heart Study,4 cigarette smoking
has been estimated to increase 1.4-fold of PAD for every 10
cigarettes per day.
History of stroke was associated with a 1.5-fold increase
in the prevalence of PAD, less than pervious reports.25,26
The association of stroke with PAD may be the result of
shared risk factors and pathophysiologic traits, since both
stroke and PAD represent “peripheral” vascular disease.
This is supported by the lack of clear association of myo-
cardial infarction with PAD,2 in line with our result.
Elevated uric acid level was associated with a 1.5-fold
increase risk of PAD among hypertensives, as described in
another study27 and in the diabetic populations.28 Mecha-
nism by which uric acid is associated with PAD remains to
be investigated.
In this study, serum total-cholesterol level was associ-
ated with PAD, consistent with the result of published
Table IV. Odds ratio and 95% confidence interval for per
patients aged 40 to 75 years (n  4716)
Crude OR (95% CI)
Age 1.02 (1.01-1.03)†
Gender 1.10 (0.89-1.36)
Body mass index 0.96 (0.94-0.99)†
Total cholesterol 1.14 (1.03-1.22)*
Triglyceride 1.03 (0.96-1.10)
Uric acid 1.29 (1.15-1.49)*
Current smoking
No 1.00 (reference)
Yes 1.44 (1.12-1.85)†
History of stroke
No 1.00 (reference)
Yes 1.56 (1.17-2.08)†
History of CAD
No 1.00 (reference)
Yes 1.08 (0.85-1.65)
Diabetic mellitus
No 1.00 (reference)
Yes 1.21 (0.86-1.72)
CAD, Coronary artery disease; OR, odds ratio; CI, confidence interval.
*P  .05.
†P  .01.
‡Adjusted for age, gender, systolic blood pressure, body mass index, triglyc
coronary heart disease.studies.12,20 BMI is a protective factor for PAD in thisstudy, similar to pervious reports.12,17,29 It is presently
unknown why BMI is a protective factor for PAD.
Despite the prevailing notion that PAD is a disease with
a predilection for men,30,31 PAD was as common in women
in our study, as well as studies previously reported.6,12,32
Although other studies have reported that PAD is
common in diabetes mellitus,33,34 we did not find associa-
tion of diabetes and PAD in this study. Our results are
consistent with that of the Cardiovascular Heart Study.12
Patients with diabetes mellitus may have calcific lower leg
arteries, rendering them incompressible and causing a
falsely elevated ABI.35 This may have attributed to the
negative result in our study and other studies. In diabetic
cases, a toe-brachial pressure index can be measured and is
more predictive of substantial arterial disease. A new report
also shows that risk factors for large-vessel PAD progression
differ from small-vessel PAD, whereas diabetes was the only
significant predictor of small-vessel PAD progression.36
Guidelines published for the detection and treatment
of hypertension (The Joint National Committee on Pre-
vention, Detection, Evaluation and Treatment of High
Blood Pressure, and European Society of Cardiology) rec-
ommend PAD as evidence of clinical cardiovascular disease.
Hypertensive patients with PAD need drug therapy no
matter which stages of hypertension they are in.37 Unfor-
tunately, due to the lack of specific PAD symptoms, clini-
cian awareness of PAD is very low in the primary care
setting,38 which translates into missed opportunities to
treatment of PAD.
Defining PAD by measurement of ABI is most accu-
al arterial disease and selected risk factors in Chinese
and gender-adjusted OR
(95% CI)
Fully adjusted model‡ OR
(95% CI )
1.02 (1.01-1.03)† 1.01 (1.00-1.02)
1.05 (1.05-1.30) 0.75 (0.56-1.01)
0.97(0.94-0.99)† 0.96 (0.93-0.98)†
1.12 (1.03-1.22)* 1.12 (1.02-1.23)*
1.04 (0.97-1.12) 1.00 (0.92-1.08)
1.25 (1.10-1.42)* 1.21 (1.10-1.59)*
1.00 (reference) 1.00 (reference)
1.63 (1.17-2.26)† 1.65 (1.18-2.29)†
1.00 (reference) 1.00 (reference)
1.50 (1.13-2.22)† 1.50 (1.12-2.00)†
1.00 (reference) 1.00 (reference)
1.12 (0.80-1.57) 1.12 (0.80-1.58)
1.00 (reference) 1.00 (reference)
1.20 (0.85-1.71) 1.13 (0.80-1.66)
total-cholesterol, uric acid, smoking status, diabetes, history of stroke, andipher
Age-rate,39 and determination of ABI is a simple, noninvasive
JOURNAL OF VASCULAR SURGERY
Volume 46, Number 2 Yang et al 301procedure that can be performed easily in the outpatient
setting.38 ABI measurement could also help to target pa-
tients at highest risk for cardiovascular death as candidates
for secondary prevention efforts.
Several limitations of the present study should be con-
sidered. First, participants were only Han nationality Chi-
nese in rural area. The results may be not applied to urban
population. Second, the cross-sectional nature of this study
limits conclusions about direction or causality of associa-
tions observed in the present study, which should be con-
firmed with a prospective study. Finally, because manymale
rural residents have been away from home to work in cities,
more female subjects were recruited in this study.
CONCLUSIONS
Our study indicates that PAD is prevalent in the mid-
dle-aed hypertensives in China. Conventional cardiovascu-
lar risk factors contribute to PAD. ABI determinations
should, therefore, be included in the routine tests of hyper-
tensives. These may help bring down the prevalence of
cardiovascular disease and prevent its progression.
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